The population of the United States is aging, and an ever-increasing number of Americans are afflicted with neurodegenerative diseases. Neurodegenerative diseases result from the gradual and progressive loss of neural cells, leading to nervous system dysfunction. According to the National Institute of Neurological Disorders and Stroke, there are more than 600 neurologic disorders, with approximately 50 million Americans affected each year.

These diseases cost the U.S. economy billions of dollars each year in direct health care costs and lost opportunities; it is estimated that \$100 billion per year is spent on Alzheimer disease (AD) alone ([@b76-ehp0113-001250]). In addition to the financial costs, there is an immense emotional burden on patients and their caregivers. As the number of elderly citizens increases, these costs to society also will increase.

Until recently, most concerns about environmental agents have centered on their potential for causing cancer. Cancer and neurodegeneration represent opposite ends of a spectrum: whereas cancer is an uncontrolled proliferation of cells, neurodegeneration is the result of the death of cells, whether due to direct cell death by necrosis or the delayed process of apoptosis. Attention is now being focused on environmental agents' potential for damaging the developing and mature nervous system, resulting in neurodegenerative diseases.

Known risk factors for neurodegenerative disease include certain genetic polymorphisms and increasing age. Other possible causes may include gender, poor education, endocrine conditions, oxidative stress, inflammation, stroke, hypertension, diabetes, smoking, head trauma, depression, infection, tumors, vitamin deficiencies, immune and metabolic conditions, and chemical exposure. Because the pathogenesis of many of these diseases remains unknown, we must consider the role of environmental factors in these diseases.

In this review we examine the human evidence for environmental etiologies for some diagnosed neurodegenerative diseases. Epidemiologic literature, not case studies or experimental animal research, was searched for relevance to an association between neurodegenerative diseases and environmental agents. We briefly review genetics and lifestyle habits (e.g., smoking, coffee, alcohol) but not other potential risk factors such as age at onset, socioeconomic status, gender, ethnicity, and education. Although it is acknowledged that the etiology of neurodegenerative diseases is often multifactorial (particularly gene--environment interactions), the purpose of this review is to examine the extent of the available epidemiologic literature solely on environmental agents.

Study Type Selection
====================

The greatest assurance for causality comes when the exposure to the environmental agent can be determined before the outcome. Because of the nature and variety of neurodegenerative diseases, the vast majority of cases are observed in the elderly population, yet the exposure could have occurred years or decades before the resulting effect. This long latency period makes it extremely difficult to track exposures before the outcome in a longitudinal fashion. A few groups have conducted studies of this type ([@b1-ehp0113-001250]; [@b7-ehp0113-001250]; [@b52-ehp0113-001250]; [@b67-ehp0113-001250]; [@b86-ehp0113-001250]; [@b91-ehp0113-001250]; [@b101-ehp0113-001250]; [@b120-ehp0113-001250]).

Because of these major constraints, many investigators have used a case--control study design that examines cases after diagnosis. The major limitation of this type of study is recall bias (see "Bias"). Ecologic studies are another type of study, with the major limitation being the inability to characterize exposure data to individuals (see "Exposure Definition").

Disease Definition
==================

Precise determinations of neurodegenerative disease can be elusive, although for approximately 80% of cases, a diagnosis made by a clinician is confirmed postmortem ([@b78-ehp0113-001250]). For many cases, a confident diagnosis can be made only during an examination of brain tissue after death. Because autopsies are not always conducted, when using mortality data such as death records, there are obvious problems if the neurologic disease in question is not listed as a primary or secondary cause of death ([@b99-ehp0113-001250]). Most studies focus on symptoms ascertained during life, and many of the criteria used to define neurologic disease are left to a certain extent to subjectivity, with inevitable associated misclassification of disease.

Also, there are difficulties associated in accurately differentiating one neurologic disease from another, particularly since many conditions may co-exist. For example [@b27-ehp0113-001250] measured "Parkinson plus syndrome," which was defined as Parkinson disease (PD) and multiple system atrophy (MSA), or PD and progressive supranuclear palsy (PSP). There is also co-morbidity of vascular conditions such as stroke or coronary heart disease. To complicate matters further, diagnostic criteria have changed or evolved over time. For example, those for MSA were revised as recently as 1998 ([@b126-ehp0113-001250]).

One solution to the problems associated with diagnosing neurodegenerative diseases would be to measure neurologic symptoms individually and early, before clinical diagnosis. Formal neuropsychologic tests can provide some objective support. Several lines of evidence have been published with this focus ([@b6-ehp0113-001250]; [@b29-ehp0113-001250]; [@b31-ehp0113-001250]; [@b57-ehp0113-001250]; [@b58-ehp0113-001250]; [@b89-ehp0113-001250]). However, there may be some uncertainty with linking early subtle effects with clinical diagnosis. For this reason, we examine in this review only those studies where there was definitive clinical diagnosis for neurodegenerative disease.

Exposure Definition
===================

A number of studies have examined the relationship between exposure to environmental agents and neurologic outcomes. Many studies involve a plethora of individual agents as a mixture, so it is understandable that some have not found an association for neurologic outcomes using a broad exposure definition. Similarly, the grouping of pesticides as an exposure category may be entirely too large. Many researchers have attempted to subdivide this class of chemicals into insecticides, herbicides, and fungicides, but even then a large number of substances could be classified within these clusters, and it remains difficult to tease out the associated environmental agent with the adverse outcome. For example, [@b7-ehp0113-001250] note the lack of information on specific pesticides because of trade secrets, although they could surmise the pesticides most often used in vineyards would be fungicides.

Accurate exposure assessment may be difficult to perform because of the retrospective aspect of case--control studies (see "Bias"). Also, assigning exposure categories may result in misclassification for ecologic studies ([@b37-ehp0113-001250]; [@b99-ehp0113-001250]) and when proxy respondents are used ([@b37-ehp0113-001250]). There is often a lack of dose--response data, and similarly, the intensity of exposure may be missed. In environmental exposure data, there may be a peak exposure not captured in averaged exposure data, or there may be an accumulation of low-level exposure that may be below the detection limit. For biomonitoring data, nonpersistent exposures will be difficult to capture with accuracy, and the organ or tissue assessed may or may not be where the chemical is deposited or where it has an effect. Finally, if for some exposures there is an earlier critical window of exposure that sets the stage for later neurologic degeneration, a focus on later exposure history may not capture early developmentally relevant exposures.

Power
=====

To find statistically significant results, investigators must have a sufficiently large study sample, or once the data are stratified the results will not be very telling. Likely this is why many investigators publish results on groups of chemicals (i.e., pesticides) rather than on specific chemicals, or on diagnosable diseases rather than on individual symptoms. Therefore, it is not surprising that little evidence exists to support an association between PD and specific pesticides ([@b29-ehp0113-001250]; [@b54-ehp0113-001250]). One study in particular did find an association for paraquat and PD ([@b68-ehp0113-001250]), and another found an association between organochlorines and alkylated phosphates and PD ([@b106-ehp0113-001250]). However, the number of studies examining specific pesticides resulting in statistically significant conclusions is limited.

Additionally, many of the case--control studies use small numbers of study participants, particularly those studies measuring biomarkers of exposure ([@b10-ehp0113-001250]; [@b27-ehp0113-001250]; [@b32-ehp0113-001250]; [@b34-ehp0113-001250]; [@b38-ehp0113-001250]; [@b60-ehp0113-001250]; [@b62-ehp0113-001250]; [@b77-ehp0113-001250]; [@b80-ehp0113-001250]; [@b84-ehp0113-001250]; [@b96-ehp0113-001250]; [@b114-ehp0113-001250]; [@b116-ehp0113-001250]; [@b122-ehp0113-001250]; [@b128-ehp0113-001250], [@b130-ehp0113-001250], [@b129-ehp0113-001250]). This limits the amount of power to detect a statistically significant association. Also, although not discussed in this review, the increasing focus on gene--environment interactions will have a major impact on the results because of the need to stratify results across genotype as well as chemical type.

Bias
====

Closely related to exposure assessment, a major difficulty for case--control studies generally is recall bias. Because the exposures tend to occur much earlier than the diagnosed outcome, the individual is asked to remember potential exposures over a long period; this is exacerbated for neurological diseases because the outcomes in question also tend to affect memory. However, those individuals with symptoms may overreport exposures because of the desire to determine a cause for their condition.

Selection bias may occur if those participating in the study are healthier than those who do not participate. This is known as the "healthy worker effect" because many occupational studies contain only those employees who have remained healthy and able to retain their job. For nonoccupational studies, those with more severe neurodegenerative diseases may participate to a lesser degree because of their reduced ability to communicate and travel to study centers.

Confounders
===========

As mentioned above, other risk factors for neurodegenerative disease may include gender, endocrine conditions, oxidative stress, infection and inflammation, nutrition, vascular conditions, depression, head trauma, tumors, and level of education. Ethnicity and culture may also have implications and provide insights into the etiology of some diseases ([@b69-ehp0113-001250]). In particular, smoking and caffeine and alcohol consumption have been postulated to have an association with neurodegenerative diseases.

Although the protective effect of smoking on PD is well known ([@b2-ehp0113-001250]; [@b92-ehp0113-001250]; [@b102-ehp0113-001250]), there is conflicting epidemiologic evidence regarding an association between smoking and risk of AD ([@b3-ehp0113-001250]; [@b66-ehp0113-001250]). There is much less evidence for an association between smoking and parkinsonian syndromes, but one study showed a protective effect for MSA but not for PSP ([@b121-ehp0113-001250]).

Similarly, caffeine consumption has generally been shown to be protective against the development of PD ([@b102-ehp0113-001250]), although there is much less consistent information for an association with AD ([@b67-ehp0113-001250]; [@b120-ehp0113-001250]). There is mixed evidence for a protective effect of alcohol and PD ([@b8-ehp0113-001250]; [@b9-ehp0113-001250]; [@b18-ehp0113-001250]; [@b30-ehp0113-001250]; [@b65-ehp0113-001250]; [@b68-ehp0113-001250]; [@b79-ehp0113-001250]; [@b85-ehp0113-001250]; [@b123-ehp0113-001250]) and less for alcohol and AD ([@b66-ehp0113-001250]; [@b119-ehp0113-001250]).

Alzheimer Disease
=================

Alzheimer disease is perhaps the prototypical degenerative disease affecting the central nervous system. AD is a chronic progressive disease characterized by memory loss and deficits in one or more of the following cognitive domains: aphasia (language disturbance), agnosia (failure to recognize people or objects in presence of intact sensory function), apraxia (inability to perform motor acts in presence of intact motor system), or executive function (plan, organize, sequence actions, or form abstractions). In addition, these deficits must be severe enough to interfere with daily life or work, and they must represent a significant decline from an earlier level of function. It is estimated that about four million Americans are currently diagnosed with AD. The prevalence rate is about 7% for individuals aged 65 or more, with the risk doubling every 5 years after age 65 ([@b72-ehp0113-001250]; [@b73-ehp0113-001250]).

Although most cases of AD are thought to be sporadic, there are at least four well-known risk factors for AD: increasing age, familial association, Down syndrome, and the apolipoprotein E4 allele ([@b14-ehp0113-001250]; [@b72-ehp0113-001250]; [@b93-ehp0113-001250]; [@b103-ehp0113-001250]; [@b125-ehp0113-001250]). Some examples of the association betwen exposure to environmental agents and AD are described briefly below.

Heavy metals are well-recognized environmental agents that affect brain development, leading to life-long impairment. Several epidemiologic studies have examined the possible link between aluminum (Al) and AD, with conflicting results. One study found Al in antiperspirants to be significantly associated with AD ([@b47-ehp0113-001250]), but others showed no association for Al in antiperspirants ([@b67-ehp0113-001250]) or in antacids ([@b12-ehp0113-001250]; [@b47-ehp0113-001250]; [@b67-ehp0113-001250]; [@b120-ehp0113-001250]). Studies examining occupational exposures of Al found slightly elevated but nonsignificant risk ([@b44-ehp0113-001250]; [@b104-ehp0113-001250]) or no association ([@b49-ehp0113-001250]). Also, no association was observed for Al in bone and AD ([@b84-ehp0113-001250]). One reason for this discrepancy in occupational studies is the inaccurate exposure assessment based on job description and rated for exposure to metals ([@b44-ehp0113-001250]). Furthermore, these comparisons may not be appropriate because of the different types of exposures, for example, dermal, oral, and inhalation.

The findings for an association between Al in drinking water and AD are also inconclusive. Two studies demonstrated statistically significant results ([@b75-ehp0113-001250]; [@b101-ehp0113-001250]), although the latter did not find a dose--response relationship. Others have found no association ([@b35-ehp0113-001250]; [@b70-ehp0113-001250]). Because of this variability, some researchers are now attempting to explore whether speciation of Al plays any role in causation of AD. For example, [@b36-ehp0113-001250] found an association with monomeric organic Al in drinking water and AD but not with other forms of Al.

Metals other than Al have also been studied for the relationship with AD but to a much lesser extent. No association was observed for occupational exposure to lead or mercury ([@b49-ehp0113-001250]), mercury from dental amalgams ([@b105-ehp0113-001250]), or increased mercury in the pituitary gland of AD cases versus controls ([@b19-ehp0113-001250]). However, a non-significant elevation of mercury in the brain was associated with AD ([@b20-ehp0113-001250]). Similarly, a statisticially significant association was observed between AD and an elevation of iron in the brain ([@b20-ehp0113-001250]) but not in the pituitary gland ([@b19-ehp0113-001250]), although these studies may have suffered from low power. Related to the storage of iron, an increase of the protein ferritin was found to be higher in the cerebral spinal fluid of patients with AD than that of controls ([@b64-ehp0113-001250]). A statisticially significant association was found between AD and an elevation of zinc in the brain ([@b20-ehp0113-001250]) but not for concentrations of zinc in hair and serum ([@b110-ehp0113-001250]) or pituitary gland ([@b19-ehp0113-001250]), although these studies may have suffered from low power. No association was observed for hair and serum concentration of copper or magnesium and AD ([@b110-ehp0113-001250]). An association was observed between AD and increased selenium levels in the brain ([@b20-ehp0113-001250]) but not in the pituitary gland ([@b19-ehp0113-001250]).

The neurologic effect of some pesticides (especially organophosphates and carbamates) on their intended targets is known, and the evidence is growing for the unintended consequences on humans. A significant association was observed between occupational exposure to pesticides in general and AD ([@b7-ehp0113-001250]), and statistical significant risk was observed for fumigants and defoliants and AD ([@b120-ehp0113-001250]). Others have not found an association for occupational ([@b7-ehp0113-001250]; [@b49-ehp0113-001250]; [@b120-ehp0113-001250]) or residential exposure to pesticides and AD ([@b37-ehp0113-001250]). [@b34-ehp0113-001250] examined the biologic burden of pesticides in AD cases and found an association between pesticides measured in the brain and AD.

Electromagnetic fields (EMFs) have been suspected as a causal factor for the development of AD. [@b112-ehp0113-001250] found a strong association for EMFs and AD, with an increased risk for males compared with females. [@b33-ehp0113-001250] found a strong but non-significant association with AD. A dose--response trend was observed for both outcomes. However, [@b45-ehp0113-001250] observed no association between EMF exposure and AD.

The few studies examining solvent exposure and the development of AD are contradictory. One study using job description as proxy for exposure assessment found a non-significant but suggestive association ([@b44-ehp0113-001250]), yet other studies ([@b49-ehp0113-001250]; [@b120-ehp0113-001250]) and a meta-analysis found no association ([@b46-ehp0113-001250]).

Parkinson Disease
=================

Parkinson disease is unique from AD in that it is characterized by abnormalities of motor control, as opposed to intellectual and personality changes. PD is characterized by resting tremors, bradykinesia (slowness of voluntary movement), rigidity, and a loss of postural reflexes. Patients with PD typically have a flat, expressionless face and walk with a stooped gait characterized by small steps. Many patients also experience severe depression.

The lifetime risk for PD is estimated to be 2 and 1.3% for men and women, respectively, and between 3.7 and 4.4% for "parkinsonism," a term used to characterize other clinical conditions characterized by akinesia and rigidity that do not meet clinical or pathologic criteria for idiopathic PD ([@b28-ehp0113-001250]). Although a number of genetic polymorphisms are linked to PD ([@b17-ehp0113-001250]), it is likely that the majority of cases of PD are not inherited but related to environmental factors. This is supported by a genetic study of twins by [@b118-ehp0113-001250], who observed that monozygotic--dizygotic concordance rates are indistinguishable, implying a lack of genetic influence and a strong probability of an environmental influence. Examples of environmental risk factors for PD are discussed below.

Substantial numbers of epidemiologic studies have found positive associations between PD and exposure to pesticides ([@b1-ehp0113-001250]; [@b5-ehp0113-001250], [@b7-ehp0113-001250]; [@b30-ehp0113-001250]; [@b51-ehp0113-001250]; [@b54-ehp0113-001250]; [@b68-ehp0113-001250]; [@b86-ehp0113-001250]; [@b99-ehp0113-001250]; [@b106-ehp0113-001250]), herbicides ([@b13-ehp0113-001250]; [@b43-ehp0113-001250]; [@b108-ehp0113-001250], [@b109-ehp0113-001250]), insecticides ([@b13-ehp0113-001250]; [@b43-ehp0113-001250]), and for residence in a fumigated home ([@b13-ehp0113-001250]). Similarly, [@b34-ehp0113-001250] found increased levels of pesticides in the brains of PD cases versus controls.

There are also a number of studies that have shown no association between PD and pesticide exposure ([@b8-ehp0113-001250]; [@b63-ehp0113-001250]; [@b65-ehp0113-001250]; [@b71-ehp0113-001250]; [@b111-ehp0113-001250]; [@b115-ehp0113-001250]), herbicide exposure ([@b71-ehp0113-001250]; [@b111-ehp0113-001250]), and fungicide exposure ([@b43-ehp0113-001250]). Some studies use a broad exposure definition for pesticides, as mentioned above.

Farming occupation and farm residence are related to pesticide exposure. A significant association was found for PD and farmworkers ([@b43-ehp0113-001250]; [@b56-ehp0113-001250]; [@b124-ehp0113-001250]) and orchard workers ([@b53-ehp0113-001250]). However, these positive findings have not been replicated by other investigators examining farming ([@b7-ehp0113-001250]; [@b8-ehp0113-001250]; [@b15-ehp0113-001250]; [@b29-ehp0113-001250]; [@b63-ehp0113-001250]; [@b65-ehp0113-001250]; [@b79-ehp0113-001250]; [@b100-ehp0113-001250]; [@b127-ehp0113-001250]) or residence on a farm ([@b13-ehp0113-001250]; [@b43-ehp0113-001250]; [@b107-ehp0113-001250]).

Residence in rural locations was found to be associated with PD in a number of studies ([@b13-ehp0113-001250]; [@b39-ehp0113-001250]; [@b56-ehp0113-001250]; [@b63-ehp0113-001250]; [@b71-ehp0113-001250]; [@b79-ehp0113-001250]; [@b96-ehp0113-001250]; [@b115-ehp0113-001250]; [@b127-ehp0113-001250]). Yet no association was found in a few other studies ([@b7-ehp0113-001250]; [@b8-ehp0113-001250]; [@b15-ehp0113-001250]; [@b107-ehp0113-001250]) and decreased risk was reported in others ([@b117-ehp0113-001250]; [@b123-ehp0113-001250]).

Also related to rural or farm living is the use of well water, possibly associated with runoff of pesticides or other environmental contaminants. A number of studies show a positive association ([@b63-ehp0113-001250]; [@b79-ehp0113-001250]; [@b96-ehp0113-001250]; [@b111-ehp0113-001250]; [@b127-ehp0113-001250]). However, many others found no association for drinking well water and the development of PD ([@b8-ehp0113-001250]; [@b15-ehp0113-001250]; [@b29-ehp0113-001250]; [@b43-ehp0113-001250]; [@b65-ehp0113-001250]; [@b68-ehp0113-001250]; [@b107-ehp0113-001250]; [@b115-ehp0113-001250]; [@b123-ehp0113-001250]), and one found an inverse relationship ([@b71-ehp0113-001250]), although many of these studies may have low power to detect outcomes, and the study designs vary.

The association between PD and exposure to metals has been intensely investigated. Welders exposed to multiple types of metals appear to be at increased risk of developing PD, particularly at an earlier age ([@b94-ehp0113-001250]). One study showed a subjective association with increased frequency of heavy metal exposure; however, this could not be confirmed ([@b106-ehp0113-001250]). Other studies showed no association for occupational exposures to heavy metals in general ([@b42-ehp0113-001250]; [@b68-ehp0113-001250]).

Results of epidemiologic studies examining exposure to specific metals have similarly been variable. Some studies showed a significant association with exposure to manganese alone ([@b29-ehp0113-001250]; [@b41-ehp0113-001250], [@b43-ehp0113-001250], [@b42-ehp0113-001250]), and [@b90-ehp0113-001250] showed a joint effect with exposure to both manganese and iron, but others have not found any association between PD and manganese ([@b109-ehp0113-001250]). This is supported by evidence showing no change in brain concentration of manganese ([@b26-ehp0113-001250], [@b23-ehp0113-001250], [@b25-ehp0113-001250]) in PD cases versus controls. No association was observed for exposure to iron alone ([@b43-ehp0113-001250]) but was observed for the combination of iron and copper ([@b41-ehp0113-001250], [@b43-ehp0113-001250], [@b42-ehp0113-001250]), iron and lead ([@b41-ehp0113-001250], [@b43-ehp0113-001250], [@b42-ehp0113-001250]), and iron and manganese ([@b90-ehp0113-001250]). There is evidence, however, that iron ([@b26-ehp0113-001250], [@b23-ehp0113-001250], [@b25-ehp0113-001250]; [@b55-ehp0113-001250]; [@b98-ehp0113-001250]; [@b113-ehp0113-001250]) or ferritin ([@b24-ehp0113-001250]) deposits to greater or lesser degrees in areas of the brain. Exposure to copper was found to be associated with PD ([@b41-ehp0113-001250], [@b43-ehp0113-001250], [@b42-ehp0113-001250]; [@b124-ehp0113-001250]), although biomonitoring studies are variable, with some showing an increase ([@b26-ehp0113-001250], [@b25-ehp0113-001250]) and another showing no change in brain concentration ([@b98-ehp0113-001250]). Exposure to Al was found to be higher in male cases than in male controls in one study ([@b124-ehp0113-001250]) but not in another ([@b109-ehp0113-001250]). For mercury, one study found that a significantly larger number of PD cases had dental amalgams than did controls ([@b106-ehp0113-001250]), and an association was observed between the concentration of mercury in the blood and urine and PD ([@b83-ehp0113-001250]), but others showed no association with exposure to mercury ([@b43-ehp0113-001250]; [@b109-ehp0113-001250]). Finally, although zinc was found in the brain tissue of patients with PD ([@b26-ehp0113-001250], [@b23-ehp0113-001250], [@b25-ehp0113-001250]), no association for zinc exposure and PD was observed in another study ([@b43-ehp0113-001250]).

Limited epidemiologic studies suggest an association between exposure to solvents and PD. One study examined exposure to organic solvents and found a statistically significant relationship to the development of PD ([@b111-ehp0113-001250]). In addition to the possibility of solvents causing PD, [@b87-ehp0113-001250], [@b88-ehp0113-001250] found that exposure to hydrocarbon solvents increased PD severity and earlier age at onset; another showed suggestive evidence of an association between solvents and PD ([@b106-ehp0113-001250]).

There are claims of an increase of PD for those working with wood or in other forms of construction. One study found a nonsignificant but highly elevated occupational risk ([@b53-ehp0113-001250]); another found a link to exposure to wood preservatives ([@b106-ehp0113-001250]); and a third found an increased risk for those having worked on construction sites ([@b51-ehp0113-001250]). However, the agent associated with PD is not determined for this exposure.

Parkinsonian Syndromes
======================

There are other neurodegenerative conditions with symptoms similar to PD, including MSA and PSP. These diseases often can be confused with PD because they have similar symptoms and may also co-exist ([@b27-ehp0113-001250]). Therefore, it is important to consider whether they have similar or distinct etiologies compared with PD and other neurodegenerative diseases.

MSA is a cluster of three related disorders, one of which is parkinsonian that is characterized by low blood pressure resulting in dizzy spells. The incidence rate is about 0.6 in 100,000 per year, with the incidence rate increasing to 3 in 100,000 in the population older than 50 years ([@b11-ehp0113-001250]; [@b126-ehp0113-001250]). The evidence of an association with environmental agents is limited. [@b82-ehp0113-001250] found MSA to be significantly associated with metal dusts and fumes, plastic monomers and additives, organic solvents, and pesticides when compared with controls. Case--control studies of biomarkers of exposure show increased concentrations of iron in the brains of patients with MSA ([@b23-ehp0113-001250], [@b25-ehp0113-001250]) and in patients diagnosed with both PD and MSA ([@b27-ehp0113-001250]) versus controls. No change in brain concentration of manganese was observed ([@b23-ehp0113-001250], [@b25-ehp0113-001250]).

PSP is a neurologic condition affecting the brainstem that also has symptoms similar to those of PD. It is characterized by movement and visual abnormalities. Little is known about the incidence rate ([@b11-ehp0113-001250]) or etiology of PSP ([@b21-ehp0113-001250]; [@b40-ehp0113-001250]; [@b88-ehp0113-001250]; [@b95-ehp0113-001250]; [@b97-ehp0113-001250]). Case--control studies examining the body burden of exposure shows iron was increased in the brains of patients with PD ([@b23-ehp0113-001250], [@b25-ehp0113-001250]) and patients with both PD and PSP ([@b27-ehp0113-001250]). However, neither iron nor Al in the brains of cases was found to be different from cases in another study ([@b55-ehp0113-001250]). Copper was decreased in the brains of patients with PD ([@b23-ehp0113-001250], [@b25-ehp0113-001250]) and manganese had no effect ([@b23-ehp0113-001250], [@b25-ehp0113-001250]).

Amyotrophic Lateral Sclerosis
=============================

Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease or Lou Gehrig's disease, is a rare neuromuscular disease with an incidence rate of about 1 in 100,000. It is characterized by muscular weakness from the degeneration of motor neurons, and like PD, intellect and personality is often unaffected. The National Institute of Neurological Disorders and Stroke reports that only 5--10% of all ALS cases can be traced to genetics, particularly to a mutation related to the superoxide dismutase 1 enzyme. This leaves the vast majority of cases without a known etiology, with the potential for environmental association briefly outlined below.

Far fewer studies have examined the association of pesticides and ALS than for both AD and PD. [@b74-ehp0113-001250] found that agricultural chemicals have a significant association with the development in ALS, with a stronger association for men than for women.

Metals may play a role in the development of ALS. Some studies have observed an association with occupation in welding or soldering ([@b4-ehp0113-001250]; [@b50-ehp0113-001250]), but not all have found metals to be related to ALS ([@b48-ehp0113-001250]; [@b74-ehp0113-001250]). More specifically, an association has been observed with exposure to lead ([@b4-ehp0113-001250]; [@b16-ehp0113-001250]; [@b32-ehp0113-001250]; [@b59-ehp0113-001250]), but no association was observed between ALS and lead levels in various tissues ([@b60-ehp0113-001250]; [@b116-ehp0113-001250]) or toenails ([@b10-ehp0113-001250]); however, these studies had limited numbers of study participants. No association was observed between exposure to zinc and ALS ([@b122-ehp0113-001250]), and the evidence from biomarker studies is inconclusive, with an increased ([@b38-ehp0113-001250]), decreased ([@b129-ehp0113-001250]), and no association observed for levels in brain tissue ([@b61-ehp0113-001250]; [@b81-ehp0113-001250]) or toenails ([@b10-ehp0113-001250]) compared with controls. However, these studies may have had limited power based on the size of the study population. Although one epidemiologic study showed no association between exposure to copper and ALS ([@b122-ehp0113-001250]), there was decreased copper concentration observed in both cerebrospinal fluid and blood ([@b61-ehp0113-001250]), and no association in toenails ([@b10-ehp0113-001250]) among patients with ALS versus controls. Mercury was associated with ALS risk ([@b32-ehp0113-001250]) but was found in lower concentrations in the blood of ALS patients versus controls ([@b80-ehp0113-001250]).

Case--control studies examining biomarkers of iron, manganese, selenium, and Al and risk of ALS were found. Increased iron levels have been observed in brain tissue ([@b62-ehp0113-001250]; [@b129-ehp0113-001250]), although not in blood ([@b81-ehp0113-001250]) or toenails ([@b10-ehp0113-001250]). An increase of manganese was observed in cervical cords ([@b77-ehp0113-001250]), both an increase ([@b61-ehp0113-001250]) and decrease ([@b81-ehp0113-001250]) in blood levels, and no difference in toenail concentration ([@b10-ehp0113-001250]) among cases versus controls. Selenium was found to be increased ([@b81-ehp0113-001250]) and decreased ([@b80-ehp0113-001250]) in blood cells, but no association was observed in toenails ([@b10-ehp0113-001250]) of patients with ALS versus controls. An increase was observed in Al in central nervous system tissue ([@b128-ehp0113-001250], [@b130-ehp0113-001250]) and cerebrospinal fluid ([@b114-ehp0113-001250]), yet others observed no association in spinal cords ([@b62-ehp0113-001250]) or toenails ([@b10-ehp0113-001250]). However, the latter two studies had small numbers of study participants, possibly limiting the power to detect an association.

A few studies found a relationship between other exposures and ALS. [@b50-ehp0113-001250] found a nonsignificant association with solvents, but the association was stronger and statistically significant for males with family history of neurodegenerative disease or thyroid disease. Others found conflicting results ([@b16-ehp0113-001250]; [@b74-ehp0113-001250]). One study found that those with a history of occupation in the manufacturing of plastics have a significant association with the development of ALS ([@b22-ehp0113-001250]). Occupations in electrical work have been implicated in the development of ALS in a few studies ([@b22-ehp0113-001250]; [@b50-ehp0113-001250]).

Conclusion
==========

Epidemiologic evidence for an association between environmental agents and neurodegenerative disease is inconclusive. The amounts of xenobiotics released into the environment are huge by any measure, and the paucity of information about their effects on various physiologic systems, including neurodevelopmental processes, represents a major gap in knowledge. To close this gap, the following broad areas of research topics need attention: *a*) better health tracking and monitoring data for chronic diseases, *b*) more comprehensive and longitudinal biomonitoring of environmental agents that can be linked with specific molecular/biochemical markers of exposure and subsequent health outcome data, and *c*) more epidemiologic research and testing of environmental agents to better define their effects on the adult and developing brain, as well as other critical organ systems.

Until such time that ethically and scientifically well-designed epidemiologic studies can provide a reasonable certainty that specific environmental agents, either alone or in combination with other agents, cause a given neurodegenerative disease, research on the environmental contribution to neurodegenerative disease needs to continue.

This article is part of the mini-monograph "Early Environmental Origins of Neurodegenerative Disease in Later Life: Research and Risk Assessment."
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